Multi-Chain Chimeric Polypeptides for TGF-β and Tissue Factor Modulation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for bronchopulmonary dysplasia (BPD) are inadequate in addressing the underlying cellular mechanisms that contribute to the disease progression, particularly the role of tissue factor in coagulation and inflammation.

Innovation Solution

Administration of a multi-chain chimeric polypeptide comprising target-binding domains that specifically bind to TGF-β receptor II and a soluble tissue factor domain, which associate through affinity domains to modulate the activity of TGF-β signaling and potentially reduce inflammation and coagulation in BPD.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments for BPD are used, then treatment is simple and existing, but they are inadequate in addressing underlying cellular mechanisms including tissue factor role in coagulation and inflammation

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidtreatment mechanism complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent employs a multi-chain chimeric polypeptide that integrates multiple functional domains: a soluble tissue factor domain (to modulate coagulation and inflammation pathways), TGF-β receptor II binding domains (to target pulmonary fibrosis mechanisms), and affinity domains for dimerization. This composite molecular structure allows simultaneous intervention in multiple disease pathways (coagulation, inflammation, fibrosis) that contribute to BPD pathology, thereby improving treatment reliability while addressing the complexity through a single multifunctional agent

Inventive Principle:

Principle #40Composite materials

2Reliability

If multi-chain chimeric polypeptide is administered, then treatment effectiveness improves by addressing multiple mechanisms, but molecular structure complexity increases

Engineering Contradiction:

Improvedisease mechanism coverageVSAvoidpolypeptide structure complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The invention merges multiple therapeutic functions into a single chimeric polypeptide molecule. The first and second chains are linked through affinity domains to form a dimer, with each chain containing a soluble tissue factor domain and TGF-β receptor II binding capability. This merging approach allows the molecule to simultaneously address coagulation abnormalities, inflammation, and fibrosis mechanisms in BPD, improving comprehensive disease mechanism coverage while presenting as a single administrable therapeutic agent

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The chimeric polypeptide is designed with universal multi-functionality to address multiple aspects of BPD pathology. The soluble tissue factor domain can modulate both coagulation and inflammation pathways, while the TGF-β receptor II binding capability targets fibrotic processes. This multi-functional design allows a single agent to intervene in multiple disease mechanisms simultaneously, improving reliability of treatment across diverse pathological processes

Inventive Principle:

Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The chimeric polypeptide effectively ameliorates symptoms of BPD by improving lung structure and function, reducing senescent cell accumulation, and restoring vascular density in hyperoxic neonates.

Implementation Method 1

the first chimeric polypeptide and the second chimeric polypeptide associate through the binding of the first domain and the second domain of the pair of affinity domains

Methodology Applied

Scientific EffectProtein-protein binding: